Source: Yahoo Finance
OpenOrphan (ORPH.L), parent company of clinical trial platform hVIVO, announced Monday the U.K.’s Medicine and Healthcare Products Regulatory Agency (MHRA) approved the Phase 1 study of the vaccine by U.S. biotech Codagenix, which is also collaborating with the Serum Institute of India — the world’s largest vaccine manufacturer.
The vaccine uses a weakened form of the coronavirus and will be tested on 48 healthy young adults, who will then be intentionally infected with the virus in order to test the vaccine’s efficacy.
The controversial trial method is said, by advocates, to be a quicker and safe method of testing a vaccine.
Codagenix chief medical officer Sybil Tasker said in a statement, “We believe COVI-VAC, a needle-free, single dose vaccine is well-suited to address potential gaps in supplying the global community, as there is likely to be significant unmet need even after the initial roll-out of first-generation COVID-19 vaccines.”